Condition

Relapsed/Refractory Multiple Myeloma clinical trials and research

• 21Clinical trials
• 17Countries

Newest Relapsed/Refractory Multiple Myeloma clinical trials

All recruiting trials (21)

• CT0596 CAR-T in relapsed/refractory multiple myeloma: a phased dose-find and efficacy study

  This study tests CT0596 CAR-T cells in adults with relapsed/refractory multiple myeloma who have already had multiple prior treatments.

  Recruiting Phase 1/2 UCARsgen Biotech Limited · Suzhou, Jiangsu and 1 other locations · NCT07760454

• RO7851624 in relapsed/refractory multiple myeloma (RRMM)

  This early-phase study tests RO7851624 in people with RRMM who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Genentech, Inc. · Parkville, Victoria and 1 other locations · NCT07558915

• KMA-targeted CAR T-cells for relapsed/refractory kappa-restricted multiple myeloma

  This study tests escalating doses of a patient’s own PMCC-COE-KMA CAR T-cells to see if they are safe and effective for relapsed/refractory kappa-restricted multiple myeloma expressing KMA.

  Recruiting Phase 1 Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria · NCT07541391

• IL-15–armored CAR-T for relapsed or refractory multiple myeloma and plasma cell leukemia

  This trial will test IL-15–armored CAR-T cell therapy to see if it helps adults with relapsed or refractory multiple myeloma or plasma cell leukemia, including those with persistent or returning MRD.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07509086

• IMV102 treatment for relapsed or refractory multiple myeloma

  This trial will try a single infusion of IMV102 in adults with relapsed or refractory multiple myeloma who have had at least three prior therapies to see if it is safe and helps control the cancer.

  Recruiting Early Phase 1 Suzhou Immunofoco Biotechnology Co., Ltd · Beijing and 3 other locations · NCT07493135

• See if SG2918 is safe for adults with relapsed/refractory multiple myeloma

  This study tests SG2918 in adults with relapsed or refractory multiple myeloma to see if it is safe and tolerable.

  Recruiting at 4 sites Phase 1/2 Hangzhou Sumgen Biotech Co., Ltd. · Zhengzhou, Henan and 3 other locations · NCT07454187

• Cemsidomide plus dexamethasone for relapsed or refractory multiple myeloma

  This will try cemsidomide with dexamethasone to see if it works and is safe for adults with relapsed or refractory multiple myeloma who have had several prior treatments.

  Recruiting at 33 sites Phase 2 C4 Therapeutics, Inc. · Huntsville, Alabama and 59 other locations · NCT07284758

• CT0596 CAR-T treatment for relapsed or refractory multiple myeloma and plasma cell leukemia

  This will try a CT0596 CAR‑T cell infusion in adults whose multiple myeloma or plasma cell leukemia has returned or not responded to prior treatments to see if it is safe and can control the disease.

  Recruiting Early Phase 1 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06730256

• CT0596 treatment for patients with relapsed or refractory multiple myeloma and plasma cell leukemia

  This study is testing a new CAR-T cell therapy called CT0596 to see if it can help people with relapsed or hard-to-treat multiple myeloma and plasma cell leukemia.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT06718270

• Testing REGN7945 with linvoseltamab for relapsed multiple myeloma

  This study is testing a new drug called REGN7945 combined with linvoseltamab to see if it helps adults with relapsed multiple myeloma better than linvoseltamab alone.

  Recruiting at 9 sites Phase 1/2 Regeneron Pharmaceuticals · Sydney, New South Wales and 8 other locations · NCT06669247

• Evaluating BCD-248 for treating relapsed or refractory multiple myeloma

  This study is testing a new treatment called BCD-248 to see if it can help people with relapsed or refractory multiple myeloma who have already tried other therapies.

  Recruiting at 7 sites Phase 2 Biocad · Kaliningrad and 19 other locations · NCT06668792

• Treatment of relapsed or refractory multiple myeloma using CAR-T cells

  This study is testing a new CAR-T cell treatment for people with relapsed or refractory multiple myeloma who have already tried three or more therapies to see if it can help them.

  Recruiting 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Kunming, Kunming, Yunnan · NCT06515262

• Comparing SG301 with standard treatment for relapsed multiple myeloma

  This study is testing if adding a new injection called SG301 to standard treatments can help people with relapsed multiple myeloma feel better and have better results.

  Recruiting at 9 sites Phase 3 Hangzhou Sumgen Biotech Co., Ltd. · Beijing, Beijing Municipality and 11 other locations · NCT06508983

• UTAA17 injection for treating relapsed or refractory multiple myeloma

  This study is testing a new injection called UTAA17 to see if it can safely help people with relapsed or refractory multiple myeloma.

  Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Suzhou, Jiangsu · NCT06279026

• Testing LBL-034 for patients with relapsed refractory multiple myeloma

  This study is testing a new treatment called LBL-034 to see if it can help people with relapsed or refractory multiple myeloma feel better.

  Recruiting at 21 sites Phase 1/2 Nanjing Leads Biolabs Co.,Ltd · Wuhu, Anhui and 20 other locations · NCT06049290

• Testing ISB 2001 for patients with relapsed or refractory multiple myeloma

  This study is testing a new treatment called ISB 2001 to see if it can help people with relapsed or refractory multiple myeloma who haven't had success with other therapies.

  Recruiting at 22 sites Phase 1 Ichnos Sciences SA · Palo Alto, California and 31 other locations · NCT05862012

• CAR T therapy targeting CD19 and BCMA for relapsed/refractory multiple myeloma

  This study is testing a new CAR T-cell therapy for adults with tough-to-treat multiple myeloma to see if it’s safe and effective.

  Recruiting at 33 sites Phase 1/2 AstraZeneca · Birmingham, Alabama and 35 other locations · NCT05850234

• CAR-GPRC5D treatment for patients with relapsed or refractory multiple myeloma or plasma cell leukemia

  This study is testing a new CAR-T cell treatment called CAR-GPRC5D to see if it can help people with relapsed or hard-to-treat multiple myeloma or plasma cell leukemia.

  Recruiting Phase 1 Nanjing IASO Biotechnology Co., Ltd. · Shanghai · NCT05759793

• CRISPR-edited CAR-T cell therapy for multiple myeloma

  This study is testing a new CAR-T cell therapy called CB-011 to see if it can safely help people with relapsed or hard-to-treat multiple myeloma.

  Recruiting at 16 sites Phase 1 Caribou Biosciences, Inc. · Birmingham, Alabama and 15 other locations · NCT05722418

• CAR-GPRC5D cell therapy for people with relapsed or refractory multiple myeloma or plasma cell leukemia

  This will try a one-time CAR-T treatment called CAR-GPRC5D after short chemotherapy in adults (18–75) whose multiple myeloma or plasma cell leukemia has returned or not responded after at least three prior treatments.

  Recruiting Phase 1 Tongji Hospital · Wuhan, Hubei · NCT05219721

• Testing sonrotoclax alone and with other treatments for multiple myeloma

  This study is testing a new treatment called sonrotoclax, alone and with other medications, to see if it helps people with a specific type of multiple myeloma that has come back or hasn’t responded to other treatments.

  Recruiting at 64 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 73 other locations · NCT04973605

Related topics

Quick answers

How many Relapsed/Refractory Multiple Myeloma clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 17 countries. The most sites are in China (13 trials), United States (5 trials), Australia (5 trials), France (3 trials), Italy (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 6, Phase 1: 6, Phase 2: 3, Early Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →